Bedrijfsoverzicht
Lixte Biotechnology Holdings, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the identification of therapeutic targets for cancer drug development and the subsequent development and commercialization of cancer therapies. The company functions within the healthcare sector, specifically the biotechnology industry, which is characterized by high research and development costs and long product development timelines. As of the latest available data, the organization maintains a market capitalization of $35.43 million and employs a team of three individuals. The market cap figure indicates that Lixte Biotechnology is a small-cap entity with limited market presence, while the absence of reported annual revenue in the provided financials suggests the company is currently in a pre-revenue or revenue-generating phase typical of clinical-stage biopharmaceutical firms where capital is primarily allocated toward advancing pipeline assets rather than generating sales income.
Financiële gezondheid
The financial profile of Lixte Biotechnology Holdings, Inc. reflects a company in a cash-burn phase, reporting a net income of $-6,078,593 over the trailing twelve months and an EBITDA that is not available due to the nature of its operations. The substantial gap between the reported revenue, which is not available for disclosure in the provided data, and the significant net loss reveals a cost structure driven heavily by research expenses, clinical trial costs, and operational overheads rather than profit generation. The company reports a free cash flow of $-1,278,703, indicating a continuous outflow of cash required to sustain its clinical programs and operational activities. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which signifies that the company has not yet achieved profitability or that its costs exceed its revenues entirely, a common characteristic of early-stage biotechnology ventures. In terms of liquidity and leverage, the company holds $5.11 million in cash against $1.03 million in debt, resulting in a debt-to-equity ratio of 9.44, which suggests a highly leveraged balance sheet relative to its equity base. Despite the high leverage, the current ratio stands at 3.88, indicating that the company possesses ample current assets to cover its short-term liabilities, thereby providing a buffer for its ongoing cash burn. Furthermore, the return on equity is -102.0% and the return on assets is -46.0%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate negative returns, a reality expected for companies still investing heavily in R&D before product approval.
Waarderingsbeoordeling
Trailing twelve-month P/E and forward P/E ratios are not available (N/A) for Lixte Biotechnology Holdings, Inc., a status that implies the market cannot value the stock based on current or expected earnings per share due to the company's lack of profitability. The available price-to-book ratio is 3.38, indicating that the market values the company's equity at a premium of 3.38 times its book value, likely reflecting the intrinsic value of its intellectual property and clinical pipeline assets which are not fully captured on the balance sheet. Since the price-to-sales and EV/EBITDA metrics are not available (N/A), these alternative valuation measures cannot be utilized to assess the company's relative value against peers, leaving investors to rely primarily on asset-based valuations or pipeline-driven metrics. Regarding trading ranges, the 52-week high is $6.26 and the 52-week low is $0.64, meaning the stock has experienced significant volatility over the past year, though the exact current trading price relative to this range requires external real-time data not provided in the facts. The stock exhibits a beta of 0.95, which suggests that its price volatility tracks the broader market movements with nearly identical intensity, indicating it does not offer significant downside or upside protection relative to the general market index.
Growth & Income
Revenue growth and earnings growth rates are not available (N/A) in the provided data, which precludes any analysis of whether earnings are growing faster or slower than revenue or the trajectory of the company's top line. As the company does not pay dividends, the dividend yield and payout ratio are not applicable (N/A), confirming that Lixte Biotechnology reinvests all available earnings and cash reserves into research, development, and clinical trial activities rather than distributing income to shareholders. The absence of a dividend policy is consistent with the company's lifecycle stage, where capital preservation and pipeline advancement take precedence over income generation for investors. Consequently, the overall growth and income profile of Lixte Biotechnology Holdings, Inc. is defined entirely by its ability to advance its lead product candidate, LB-100, through phase 1b clinical trials without the distraction of shareholder dividend expectations.